BLU.TO - BELLUS Health Inc.
| Previous Close | 0.97 |
| Open | 0.98 |
| Bid | 0.95 x 0 |
| Ask | 1.00 x 0 |
| Day's Range | 0.98 - 1.00 |
| 52 Week Range | 0.33 - 1.20 |
| Volume | 54,000 |
| Avg. Volume | 423,533 |
| Market Cap | 118.996M |
| Beta (3Y Monthly) | -0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.00 |
- Simply Wall St.•8 days ago
What Does BELLUS Health Inc’s (TSE:BLU) Ownership Structure Look Like?
A look at the shareholders of BELLUS Health Inc (TSE:BLU) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to Read More...
- Baystreet•21 days ago
Stocks in play: BELLUS Health Inc.
Announced the appointment of a world-class clinical advisory board. The CAB will provide strategic guidance ...
- CNW Group•2 months ago
BELLUS Health to Present at Baird 2018 Global Healthcare Conference
LAVAL, QC, Aug. 30, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including its lead program BLU-5937 for the treatment of chronic cough, on Thursday September 6, 2018 at 2:00 pm ET at the Baird 2018 Global Healthcare Conference in New York. Following the event, the archived webcast and BELLUS Health's presentation will be available on the Company's website at www.bellushealth.com.
- Baystreet•2 months ago
BELLUS, Eastwood at 52-week highs
BELLUS Health Inc. (T.BLU) reached a 52-week high of 86 cents Wednesday. No news announcements today Eastwood ...
- ACCESSWIRE•2 months ago
Today's Research Reports on Resverlogix, IMV, BELLUS Health and Hamilton Thorne
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- CNW Group•2 months ago
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2018
LAVAL, QC, Aug. 8, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the second quarter ended June 30, 2018.
- Simply Wall St.•2 months ago
How Should Investors React To BELLUS Health Inc’s (TSE:BLU) CEO Pay?
Roberto Bellini is the CEO of BELLUS Health Inc (TSE:BLU), which has recently grown to a market capitalization of CA$68.11m. Recognizing whether CEO incentives are aligned with shareholders is aRead More...
- CNW Group•3 months ago
BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
LAVAL, QC, July 19, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that the Japan Patent Office has issued a decision to grant Japanese Patent No. 2015-555508, which grants claims covering the composition of matter of BELLUS Health's lead drug candidate, BLU-5937, and related imidazopyridine compounds, in addition to pharmaceutical compositions comprising BLU-5937 and uses thereof. With the grant of this new Japanese patent, BLU-5937 has now obtained patent protection with claims covering its composition of matter in all major pharmaceutical markets, including the U.S., Europe, Japan and China.
- ACCESSWIRE•3 months ago
Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics
LONDON, UK / ACCESSWIRE / July 9, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 1.81 points, or 0.24%, to finish at 740.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).
- ACCESSWIRE•3 months ago
Today's Research Reports on Acerus Pharmaceuticals, IMV, Valeant Pharmaceuticals and BELLUS Health
NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
- CNW Group•3 months ago
BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937
LAVAL, QC, July 9, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced the initiation of healthy subjects dosing in a Phase 1 clinical study for BLU-5937, its lead drug candidate for the treatment of chronic cough. Preclinical studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception, with an excellent safety profile. The main objectives of the Phase 1 clinical study are to assess the safety, tolerability (including taste perception) and pharmacokinetic profile of BLU-5937 in healthy subjects.
- CNW Group•4 months ago
BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
LAVAL, QC, June 27, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today presented preclinical data on its lead drug candidate, BLU-5937 for the treatment of chronic cough. Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, provided a review of the data at the 2018 International Cough Symposium in London, UK. In summary, animal studies demonstrated that BLU-5937 is a highly selective P2X3 antagonist exhibiting a potent anti-tussive effect without affecting taste perception.
- Baystreet•4 months ago
Stocks in play: BELLUS Health Inc.
Announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present ...
- CNW Group•4 months ago
BELLUS Health to Present at the 2018 International Cough Symposium
LAVAL, QC, June 20, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Dr. Denis Garceau, BELLUS Health's Senior Vice President, Drug Development, will present the Company's lead drug candidate for the treatment of chronic cough, BLU-5937, at the 2018 International Cough Symposium in London, UK, on Wednesday June 27, 2018 at 4:30 pm BST (11:30 am EDT). A copy of the presentation will be available on the Company's website at www.bellushealth.com following the event.
- ACCESSWIRE•4 months ago
Today's Research Reports on Aptose Biosciences, Fennec Pharmaceuticals, Valeant Pharmaceuticals and BELLUS Health
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
- ACCESSWIRE•4 months ago
Today's Free Reports BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics
LONDON, UK / ACCESSWIRE / June 7, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange gained 7.25 points, or 0.94%, to finish at 775.10. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).
- CNW Group•5 months ago
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2018
- Completed studies required to submit clinical trial application for BLU-5937 for chronic cough - - Announces voting results from Annual Meeting - LAVAL, QC , May 15, 2018 /CNW/ - BELLUS Health Inc. (TSX: ...
- ACCESSWIRE•5 months ago
Today’s Research Reports on Oncolytics Biotech, CardioComm Solutions, BELLUS Health and Aphria
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
- ACCESSWIRE•5 months ago
Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
LONDON, UK / ACCESSWIRE / May 04, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. The TSX Venture Exchange shaved off 0.86 points, or 0.11%, to finish at 771.25. Today's stocks of interest consist of: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX).
- CNW Group•6 months ago
BELLUS Health Responds to Recent Share Price Appreciation and Increased Trading Activity
LAVAL, QC, April 30, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today responded to a request from the Investment Industry Regulatory Organization of Canada (IIROC) to comment on recent trading activity of BELLUS Health's shares. BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. Its pipeline of projects includes the Company's lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.
- CNW Group•6 months ago
BELLUS Health to Present at Bloom Burton & Co. Healthcare Investor Conference
LAVAL, QC, April 26, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company, including an update on its lead program, BLU-5937 for the treatment of chronic cough, on Thursday May 3, 2018 at 9:30 am ET at the 2018 Bloom Burton & Co. Healthcare Investor Conference. The Bloom Burton & Co. Healthcare Investor Conference will be held at the Sheraton Centre Toronto Hotel on May 2 and 3, 2018. BELLUS Health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need.
- ACCESSWIRE•6 months ago
Today’s Research Reports on Acerus Pharmaceuticals, TSO3, BELLUS Health and ImmunoVaccine
NEW YORK, NY / ACCESSWIRE / April 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
- ACCESSWIRE•6 months ago
Canadian Exchanges Stock Scanner BELLUS Health, Helius Medical Technologies, Resverlogix and Crescita Therapeutics
LONDON, UK / ACCESSWIRE / April 4, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, ...
- ACCESSWIRE•7 months ago
Toronto Exchanges Stock Review BELLUS Health Helius Medical Technologies Resverlogix and Crescita Therapeutics
LONDON, UK / ACCESSWIRE / March 5, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: BELLUS Health, Helius Medical Technologies, ...
- CNW Group•8 months ago
BELLUS Health Reports Financial and Operating Results for the Year Ended December 31, 2017
LAVAL, QC, Feb. 21, 2018 /CNW/ - BELLUS Health Inc. (TSX:BLU.TO - News) ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the year ended December 31, 2017.
